Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Argenx is spending billions to push beyond Vyvgart

Six months into her term as CEO of rare disease drugmaker argenx, Karen Massey has overseen two acquisitions worth a combined potential of about $3.4 billion as the company seeks to build a broader immunology ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 13 November →